Global /Japan /Healthcare /Biotechnology /130A

Veritas In Silico Inc.

130A

• TSE: 130A • Delayed

456JPY -3.6%

2.85 USD

As of 5 June 2026, Veritas In Silico Inc. has a market cap of $19.17M USD, ranking #37390 globally and #3597 in Japan. It ranks #3348 in the Healthcare sector, and #660 in the Biotechnology industry.

Global Rank

37390

Country Rank

3597

Sector Rank

3348

Industry Rank

660

Key Stats

Market Cap

$19.17MUSD

3.07B JPY

Enterprise Value

$7.77MUSD

1.24B JPY

Revenue (TTM)

$569.51KUSD

91.14M JPY

EBITDA (TTM)

-$2.38MUSD

-381.0M JPY

Net Income (TTM)

-$2.66MUSD

-425.67M JPY

PS Ratio

33.7

PB Ratio

1.7

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Shingo Nakamura open_in_new

Employees

Founded

2016

Website

veritasinsilico.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.6%	-1.9%	-0.2%	-4.4%	-17%	-1.5%	-31%	-80%	-80%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	130A 株式会社 Veritas In Silico ISIN: JP3155340007 Shares Out.: Shares Outstanding: 6.487M¹ Shares Float: 2.311M² TV: TradingView: TSE: 130A SA: Stock Analysis: TYO: 130A YF: Yahoo Finance: 130A.T GF: Google Finance: TYO: 130A BA: Barron's: 130A MS: Morningstar: XTKS: 130A	456 JPY	TV: TradingView: TSE: 130A SA: Stock Analysis: TYO: 130A YF: Yahoo Finance: 130A.T GF: Google Finance: TYO: 130A BA: Barron's: 130A MS: Morningstar: XTKS: 130A

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Veritas In Silico Inc.

Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 5K%	-	Japan
PeptiDream Inc. TSE: 4587	$929.34M 148.73B JPY 5K%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.28M 84.22B JPY 3K%	-	Japan
Cuorips Inc. TSE: 4894	$349.84M 55.99B JPY 2K%	-	Japan
Innovacell Inc. TSE: 504A	$169.93M 27.19B JPY 786%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 493%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 951K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 834K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 250K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.36B 68.19T KRW 231K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 224K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 222K%	37.2	Switzerland

chevron_leftBack